Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphalan Announces FD Approval of Cuvrior\u2122 for the Treatment of Adult Patients With Stable Wilson\u2019s Disease Who Are De-coppered and Tolerant to Penicillamine","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphalan Announces Data From Secondary Analyses of the CHELATE Trial for Maintenance Patients With Wilson\u2019s Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphalan Announces Publication of Results from the CHELATE Trial in The Lancet Gastroenterology & Hepatology","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphalan Announces US Commercial Launch of Cuvrior\u2122 for the Treatment of Wilson Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Orphalan","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orphalan Announces China NMPA's Approval of Its Trientine Tetrahydrochloride Product for The Treatment of Wilson Disease","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Orphalan

    Menu

    Orphalan

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Orphalan

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orphalan Announces China NMPA's Approval of Its Trientine Tetrahydrochloride Product for The Treatment of Wilson Disease

              Details:

              Cuprior (trientine tetrahydrochloride) is a copper chelator which eliminates absorbed copper from the body by forming a stable complex that is then eliminated through urinary excretion. It is approved for the treatment of Wilson disease.

              Lead Product(s): Trientine Tetrahydrochloride

              Therapeutic Area: Genetic Disease Product Name: Cuprior

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 18, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orphalan

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orphalan Announces US Commercial Launch of Cuvrior™ for the Treatment of Wilson Disease

              Details:

              Cuvrior (trientine hydrochloride) is a copper chelator that forms a complex with absorbed copper and then gets eliminated through urinary excretion. It is available in US for the treatment of stable Wilson disease who are de-coppered and tolerant to penicillamine.

              Lead Product(s): Trientine Tetrahydrochloride

              Therapeutic Area: Genetic Disease Product Name: Cuvrior

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orphalan

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orphalan Announces Publication of Results from the CHELATE Trial in The Lancet Gastroenterology & Hepatology

              Details:

              Using this NCC measurement Cuvrior (trientine tetrahydrochloride) was determined to be non-inferior to penicillamine at primary endpoint of study (24 weeks), with same observation at end of extension phase of study in patients receiving maintenance penicillamine therapy.

              Lead Product(s): Trientine Tetrahydrochloride

              Therapeutic Area: Genetic Disease Product Name: Cuvrior

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 30, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orphalan

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orphalan Announces Data From Secondary Analyses of the CHELATE Trial for Maintenance Patients With Wilson’s Disease

              Details:

              Cuvrior™ (trientine tetrahydrochloride) is an oral trientine formulation. In the U.S., trientine tetrahydrochloride has been granted Orphan Drug Designation for the treatment of Wilson’s disease.

              Lead Product(s): Trientine Tetrahydrochloride

              Therapeutic Area: Genetic Disease Product Name: Cuvrior

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Orphalan

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Orphalan Announces FD Approval of Cuvrior™ for the Treatment of Adult Patients With Stable Wilson’s Disease Who Are De-coppered and Tolerant to Penicillamine

              Details:

              Orphalan recently completed a global phase III trial, CHELATE, which met its primary efficacy endpoint by demonstrating that Cuvrior, a new salt of trientine (trientine tetrahydrochloride) was non-inferior to penicillamine as measured by non-ceruloplasmin copper.

              Lead Product(s): Trientine Tetrahydrochloride

              Therapeutic Area: Genetic Disease Product Name: Cuvrior

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY